Introduction Skin cancer is the most common type of cancer and is classified in melanoma
and non-melanoma cancers, which include basal cell, squamous cell, and Merkel cell …

… biomarkers of response to ICI melanoma therapies, their pre-treatment predictive values, and
their utility as on-treatment … specific, and optimized biomarkers of response to ICI therapies. …

… of care for the management of BRAF-mutated melanoma but definitely provided further …
focused on immune biomarkers, are needed to optimize the upfront treatment strategy and …

… a standard of care for the treatment of patients with advanced melanoma. At present, …
for advanced melanoma; a phase II/III clinical trial of nivolumab combined with a novel anti-LAG3 …

… available therapeutic options for NRAS mut melanoma patients … most promising novel
therapeutic approaches for melanoma … Subsequent efforts have focused on dose optimization and …

… biomarkers involved in tumor development may become critical therapeutic targets for anti-tumor
therapy… Regarding the HLA allele, the survival rate of advanced melanoma patients with …

… correlation with patient response to anti-PD1 for 411 melanoma samples complied from 6
cohorts. Furthermore, mapping drug target data to the top genes in our association prediction …

… The optimization of treatment strategies with current drugs, the validation of promising …
agents will meaningfully improve, in the near future, the clinical management of these patients. …

… —may represent potential therapeutic targets of EMT: IL-6 … treatment with endostatin has
proved no effect on the inhibition of melanoma VM (148), thus portraying aggressive melanoma …

… promising drug targets and biomarkers in melanoma. … be functionalized and delivery optimized
by surface modification … proved to be promising drug targets or drug themselves in both …